Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
W. Wolfgang Fleischhacker, Jana Podhorná, Martina Gröschl, Sanjay Hake, Yihua Zhao, Songqiao Huang, Richard S.E. Keefe, Michael Desch, Ronald Brenner, David P. Walling, E. Mantero-Atienza, Kazuyuki Nakagome, Stephane Pollentier
Topics & Concepts
PlaceboAdverse effectMedicineClinical endpointInternal medicineSchizophrenia (object-oriented programming)Randomized controlled trialClinical trialPositive and Negative Syndrome ScalePsychiatryPsychosisAlternative medicinePathologySchizophrenia research and treatmentAmino Acid Enzymes and MetabolismNeurotransmitter Receptor Influence on Behavior